HighTower Advisors
ALNY icon

HighTower Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

HighTower Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-300
Closed -$4K – 2214
2017
Q1 		$4K Buy
+300
New +$13.9K ﹤0.01% 2044

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors's ALNY Position: Q1 2026 in Review

HighTower Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.59% in Q1 2026, selling an estimated $215K and leaving 105,859 shares worth $35M. The position accounts for 0.04% of the portfolio, ranked #452.

HighTower Advisors first reported a position in ALNY in Q3 2015 and has held it in 38 quarters since. The position peaked at $50.4M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • HighTower Advisors held 105,859 shares of Alnylam Pharmaceuticals worth $35M as of Q1 2026.
  • HighTower Advisors sold 632 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $215K.
  • Alnylam Pharmaceuticals made up 0.04% of HighTower Advisors's portfolio in Q1 2026, its #452 holding.
  • HighTower Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2015 and has held it in 38 quarters since.
  • HighTower Advisors's Alnylam Pharmaceuticals position peaked at $50.4M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.